Antidepressant Not Working After 8 Weeks: A Doctor-Reviewed Decision Path

You have been taking this medication for eight weeks. Your mood is not better. Maybe it is slightly worse. Or maybe there is nothing: no change in either direction, which can feel like its own kind of failure.

This is one of the most common and most distressing moments in psychiatric treatment. It is also one of the most mismanaged. Patients stop the medication without telling their prescriber. Prescribers declare the medication failed without checking whether the trial was actually adequate. And both parties move forward without the structured decision-making that evidence-based guidelines recommend.

Eight weeks without response is a clinical signal. It is not a dead end. Here is the decision path the evidence actually supports.

What “Not Working” Actually Means Clinically

Clinicians typically distinguish between three patterns when assessing antidepressant response at 8 weeks:

No response: Less than 25% reduction in baseline symptom severity (typically measured by PHQ-9). Core symptoms unchanged or worsened.

Partial response: Between 25% and 50% improvement. Better, but not enough. This is the most common outcome from a first antidepressant, and it has a different clinical decision path than no response.

Remission: PHQ-9 score below 5 or equivalent. Symptoms substantially resolved. This is the treatment goal.

Clinical practice guidelines specify that if less than 25% improvement is observed after 4 weeks of pharmacotherapy, a treatment reappraisal should be conducted. If there is less than 50% improvement after 6 to 8 weeks at a maximum tolerable dose with good medication compliance, a change in antidepressant may be considered. These clinical thresholds guide the decision path.

Three Questions Before Changing Anything

Before a prescriber concludes that a medication has failed, three questions need definitive answers. Many apparent treatment failures are actually inadequate trials.

Was the Dose Actually Therapeutic?

Most antidepressants are started below their therapeutic threshold to minimize early side effects. Sertraline typically starts at 50mg but may require 100 to 200mg for full effect. Escitalopram starts at 10mg; the therapeutic range extends to 20mg. When using a single antidepressant from treatment initiation, something clinically important should happen every two weeks: if there is no clinically detectable improvement at week 2, the dose should be increased if well tolerated. At week 4 without 50% improvement, the dose could be increased further or a switch considered. Many patients reach week 8 having never been titrated to an adequate therapeutic dose.

Was Adherence Consistent?

Research across nearly 185,000 patients found that approximately 30% discontinue antidepressants within the first month and up to 60% within three months. Irregular adherence produces data that looks like non-response but is actually insufficient medication exposure. A prescriber assessing an 8-week trial needs to know whether it was 8 weeks of consistent dosing, or 8 weeks with frequent misses.

Are There Comorbidities or Medical Factors?

Mechanisms of treatment-resistant depression involve a complex interplay of neurobiological, clinical, and environmental factors, including medical conditions that may be maintaining depression independently of the antidepressant’s mechanism of action. Untreated thyroid dysfunction, vitamin B12 deficiency, chronic sleep apnea, alcohol use, and unrecognized anxiety comorbidity can all prevent an adequate antidepressant trial from producing response. These factors need to be identified and addressed before concluding the medication failed.

The 8-Week Benchmark: What the Evidence Says

The 6 to 8 week reassessment window comes from decades of clinical trial data showing that most antidepressant response, when it occurs, is visible within this timeframe. But the benchmark has important nuances.

A systematic review of nine randomized controlled trials involving 3,466 adults found that just over one-fifth of people who had not responded by week 4 achieved at least a 50% reduction in depressive symptoms between weeks 5 and 8. Among those not responding by week 8, approximately 1 in 10 responded between weeks 9 and 12. Overall response rates were 42% after four weeks, 55% after eight weeks, and 59% after twelve weeks.

These numbers matter clinically. Declaring a medication failed at exactly 8 weeks without checking whether the trial was adequate discards a subset of patients who would have responded with more time at a therapeutic dose. The clinical decision window is real: something meaningful should happen by week 8, but the quality of the trial has to be evaluated first.

The Three Clinical Paths at 8 Weeks

Path 1: No Response at Adequate Dose and Adherence

If dose was therapeutic, adherence was consistent, and there is less than 25% symptom improvement at 8 weeks, evidence-based options include: switch to a different SSRI, switch to a different class (SNRI, bupropion, mirtazapine), or augment with a second medication. APA practice guidelines recommend that when a patient has not responded to an antidepressant trial, options include switching to a different antidepressant or augmenting the current regimen with a second agent. The choice between switching and augmenting depends on degree of partial response, tolerability, and patient preference.

Path 2: Partial Response at 8 Weeks

Between 25% and 50% improvement at 8 weeks is not failure. It is a partial response, which typically calls for different decisions than no response. Options include dose optimization (if not yet at maximum tolerable dose), extending the trial by 4 to 6 more weeks, or adding augmentation. Switching outright from a partial response is generally not the first move in clinical guidelines, because it discards an ongoing response in favor of starting over.

Path 3: Adequate Response but Residual Symptoms

Some patients reach week 8 substantially better but not fully themselves: mood improved, but sleep still disrupted, energy not recovered, or cognitive fog persisting. Residual symptoms are among the strongest predictors of relapse and require specific clinical attention. Assessment should include whether dose optimization, a treatment addition, or a psychotherapy component would address these gaps.

Why Continuity of Data Matters at Every Transition

The quality of the decision at the 8-week mark depends entirely on the quality of the data available to the prescriber. A prescriber working from a 15-minute appointment with a patient reconstructing 8 weeks from memory is making a consequential treatment decision from a very thin information base.

The questions that matter most at this decision point: Was adherence actually consistent, or were there patterns of missing doses? Did symptoms improve slightly in weeks 2 through 4 and then plateau, or was there never any movement? Were side effects significant enough to suggest an underdosed trial rather than a genuinely non-responsive one? These questions have answers in daily monitoring data. They rarely have complete answers in a quarterly appointment conversation.

Continuity of monitoring across an antidepressant trial does not just support the adherence and side effect management that keeps patients in treatment. It produces the data that makes the week-8 reassessment decision evidence-based rather than a guess.

How SiggyMD Approaches Non-Response

SiggyMD’s prescribers do not reach the 8-week mark without a longitudinal clinical picture. Daily check-in data captures adherence patterns, symptom trajectory, sleep quality, and side effect experience from the first day of treatment. By week 8, the prescriber is reviewing a documented record, not asking the patient to reconstruct their experience from memory.

“The decision at 8 weeks is only as good as the information behind it,” says Daniel Montville, MD, Psychiatrist at SiggyMD. “When I can see that a patient was adherent, had a modest early response in weeks 2 through 3, and their symptoms have plateaued at about 30% improvement, I am looking at a partial response. That is a different clinical path than no response. The data lets me make that distinction. Without it, I am guessing.”

What Members Are Saying

AL

A.L., 37

Major Depressive Disorder

“My previous prescriber said the medication wasn’t working at 6 weeks and switched me immediately. At Siggy, my prescriber looked at my check-in data and noticed I had been taking it inconsistently. We gave the same medication another 6 weeks at a consistent dose. It worked.”

JB

J.B., 44

Depression with Anxiety

“I assumed I had treatment-resistant depression after two antidepressants. My prescriber at Siggy reviewed my history and said both trials had been at starting doses for under 6 weeks. Neither was an adequate trial. We ran a real trial. It was the first one that actually worked.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

Bottom Line

Eight weeks on an antidepressant without response is a clinical signal to reassess, not a reason to give up on treatment. Before concluding the medication failed, three questions need answers: Was the dose therapeutic? Was adherence consistent? Are there medical or comorbid factors blocking response?

If the trial was actually adequate and there is still no response, the evidence-based decision path is structured and specific. Partial response, no response, and residual symptoms each call for different clinical moves. Getting that decision right requires the data to make it. A prescriber working from 60 minutes of annual contact does not have it. One with 8 weeks of daily adherence, symptom, and side effect data does.

Sources

• NIHR Evidence. A fifth of people who have no improvement on antidepressants at four weeks respond if given more time. NIHR Evidence. Accessed June 2026.

• Shrivastava A, et al. Clinical Practice Guidelines for the management of Depression. Indian Journal of Psychiatry. 2017;59(Suppl 1):S34-S50.

• Blier P. Optimal use of antidepressants: When to act? Journal of Psychiatry and Neuroscience. 2009;34(1):E1-E2.

• American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. APA. Accessed June 2026.

• Jha MK, Trivedi MH. Mechanisms of treatment-resistant depression: a complex interplay of neurobiological, clinical, and environmental factors. Frontiers in Psychiatry. 2023;13:1095977.

• Rossom RC, et al. Antidepressant Adherence Across Diverse Populations and Healthcare Settings. Depression and Anxiety. 2016;33(8):765-774.

• Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a Brief Depression Severity Measure. Journal of General Internal Medicine. 2001;16(9):606-613.